The treatment of paroxysmal nocturnal hemoglobinuria has been revolutionized by the
introduction of the anti-C5 agent eculizumab; however, eculizumab is not the cure for …

Background The present review is part of the ESCMID Study Group for Infections in
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …

Ravulizumab, a new complement component C5 inhibitor administered every 8 weeks, was
noninferior to eculizumab administered every 2 weeks in complement-inhibitor–naive …

Abstract Ravulizumab (ALXN1210), a new complement C5 inhibitor, provides immediate,
complete, and sustained C5 inhibition. This phase 3, open-label study assessed the …

Background The haematological benefit of standard-of-care anti-C5 treatment for haemolytic
paroxysmal nocturnal haemoglobinuria is limited by residual intravascular haemolysis or …

Complement C5 inhibition is the standard of care (SoC) for patients with paroxysmal
nocturnal hemoglobinuria (PNH) with significant clinical symptoms. Constant and complete …

Atypical hemolytic uremic syndrome (aHUS) is a genetic, life-threatening disease
characterized by uncontrolled complement activation, systemic thrombotic microangiopathy …

Adverse pregnancy outcomes significantly contribute to morbidity and mortality for mother
and child, with lifelong health consequences for both. The innate and adaptive immune …

Paroxysmal nocturnal haemoglobinuria (PNH) is characterized by complement‐mediated
intravascular haemolysis, severe thrombophilia and bone marrow failure. While for patients …

Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by uncontrolled terminal
complement activation and subsequent intravascular hemolysis (IVH). C5 inhibitors prevent …